Active Ingredient(s): Avalglucosidase Alfa-ngpt
FDA Approved: * August 6, 2021
Pharm Company: * GENZYME CORP
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nexviazyme Overview

Avalglucosidase alfa, sold under the brand name Nexviazyme, is an enzyme replacement therapy medication used for the treatment of glycogen storage disease type II (Pompe disease).[1][2] The most common side effects include headache, fatigue, diarrhea, nausea, joint pain (arthralgia), dizziness, muscle pain (myalgia), itching (pruritus), vomiting, difficulty breathing (dyspnea), skin redness (erythema), feeling of “pins and needles” (paresthesia) and...

Read more Nexviazyme Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nexviazyme Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Avalglucosidase Alfa-ngpt
  • Injection: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Avalglucosidase Alfa-ngpt or a similar ingredient: (1 result)